Novita Therapeutics ("Novita") announced today the closing of a follow-on round of angel financing, bringing the total cash investment to $930,000 since the company's founding in November 2009.

In related news, Novita also announced the signing of an agreement with Cirtec Medical, Inc., for the design of a novel, implantable cardiovascular device. The device is intended to treat a chronic condition impacting more than 200,000 patients in the U.S., and will provide a new treatment option that will reduce morbidity and mortality for these patients, while also reducing the overall cost of their care.

"We are pleased to take the next step as a company and make the transition from research to product development," said Nicholas Franano, M.D., President and CEO of Novita. "With the support of our new investors and manufacturing partner Cirtec Medical, we expect great things."

Cirtec Medical Chief Executive Officer Barry Smith said, "We are very excited about the potential of Novita's technology and look forward to working with them to develop and ultimately commercialize this important new product."

About Novita Therapeutics
Novita Therapeutics, LLC is a privately held biopharmaceutical and medical device company headquartered in Lenxa, Kansas. For additional information, please visit www.novitatherapeutics.com.

About Cirtec Medical
Cirtec Medical is a leader in outsourced medical solutions for the design and manufacture of minimally invasive medical devices, active and passive medical implants, medical electronics, and instrumentation, with offices in East Longmeadow, Massachusetts and Los Gatos, California. For additional information, please visit www.cirtecmed.com.

COMPANY CONTACT:
F. Nicholas Franano, M.D.
President & CEO
913-440-4439
nfranano@novitatherapeutics.com

PRESS CONTACT:
Michael Kanaley
816-994-9644
michael.kanaley@global-prairie.com